Hong Liu-Seifert
Overview
Explore the profile of Hong Liu-Seifert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
2257
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Donohue M, Model F, Delmar P, Volye N, Liu-Seifert H, Rafii M, et al.
Alzheimers Dement
. 2020 Apr;
16(5):797-803.
PMID: 32270600
In clinical trials in populations with mild cognitive impairment, it is common for participants to initiate concurrent symptomatic medications for Alzheimer's disease after randomization to the experimental therapy. One strategy...
2.
Liu-Seifert H, Schumi J, Miao X, Tian Y, Rabbia M, Andersen S, et al.
Ther Innov Regul Sci
. 2020 Feb;
54(2):396-403.
PMID: 32072596
Alzheimer's disease (AD) has increasingly been recognized as a huge unmet medical need. Currently, there is no approved drug to cure, prevent, or even slow down the disease. It is...
3.
Mease P, Smolen J, Behrens F, Nash P, Liu Leage S, Li L, et al.
Ann Rheum Dis
. 2019 Sep;
79(1):123-131.
PMID: 31563894
Objectives: To compare efficacy and safety of ixekizumab (IXE) to adalimumab (ADA) in biological disease-modifying antirheumatic drug-naïve patients with both active psoriatic arthritis (PsA) and skin disease and inadequate response...
4.
Liu-Seifert H, Siemers E, Holdridge K, Andersen S, Lipkovich I, Carlson C, et al.
Alzheimers Dement (N Y)
. 2018 Jun;
1(2):111-121.
PMID: 29854931
Introduction: Solanezumab is an anti-amyloid monoclonal antibody in clinical testing for treatment of Alzheimer's disease (AD). Its mechanism suggests the possibility of slowing the progression of AD. Methods: A possible...
5.
Honig L, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, et al.
N Engl J Med
. 2018 Jan;
378(4):321-330.
PMID: 29365294
Background: Alzheimer's disease is characterized by amyloid-beta (Aβ) plaques and neurofibrillary tangles. The humanized monoclonal antibody solanezumab was designed to increase the clearance from the brain of soluble Aβ, peptides...
6.
Liu-Seifert H, Andersen S, Case M, Sparks J, Holdridge K, Wessels A, et al.
J Biopharm Stat
. 2017 Apr;
27(6):1104-1114.
PMID: 28402165
Little research has been conducted on the statistical properties of composite measures comprising linear combinations of continuous component scales. We assessed the quantitative relationship between the composites and their individual...
7.
Kahle-Wrobleski K, Ye W, Henley D, Hake A, Siemers E, Chen Y, et al.
Alzheimers Dement (Amst)
. 2017 Feb;
6:82-90.
PMID: 28229126
Introduction: Characterization of the quality of life (QOL) in Alzheimer's disease (AD) scale within the context of a clinical trial may inform its applicability in future trials. Methods: Using data...
8.
Siemers E, Holdridge K, Sundell K, Liu-Seifert H
Alzheimers Dement (Amst)
. 2016 May;
2:105-12.
PMID: 27239541
Introduction: Effectiveness of Alzheimer's disease (AD) treatments is commonly evaluated with coprimary outcomes; cognition with function to ensure clinical meaningfulness of a cognitive effect. Methods: We reviewed the literature for...
9.
Liu-Seifert H, Siemers E, Price K, Han B, Selzler K, Henley D, et al.
J Alzheimers Dis
. 2015 Sep;
47(1):205-14.
PMID: 26402769
Background: The temporal relationship of cognitive deficit and functional impairment in Alzheimer's disease (AD) is not well characterized. Recent analyses suggest cognitive decline predicts subsequent functional decline throughout AD progression....
10.
Siemers E, Sundell K, Carlson C, Case M, Sethuraman G, Liu-Seifert H, et al.
Alzheimers Dement
. 2015 Aug;
12(2):110-120.
PMID: 26238576
Introduction: EXPEDITION and EXPEDITION2 were identically designed placebo-controlled phase 3 studies assessing effects of solanezumab, an antiamyloid monoclonal antibody binding soluble amyloid-β peptide, on cognitive and functional decline over 80 ...